148 related articles for article (PubMed ID: 34428735)
1. Intrinsic relative preference profile of pan-kinase inhibitor drug staurosporine towards the clinically occurring gatekeeper mutations in Protein Tyrosine Kinases.
Ren Z; Li Q; Shen Y; Meng L
Comput Biol Chem; 2021 Oct; 94():107562. PubMed ID: 34428735
[TBL] [Abstract][Full Text] [Related]
2. Systematic response of staurosporine scaffold-based inhibitors to drug-resistant cancer kinase mutations.
He Y
Arch Pharm (Weinheim); 2020 Jun; 353(6):e1900320. PubMed ID: 32285482
[TBL] [Abstract][Full Text] [Related]
3. Systematic profiling of staralog response to acquired drug resistant kinase gatekeeper mutations in targeted cancer therapy.
Yang Y; Qiu Y; Liu X; Liu Y; Yin Y; Li P
Amino Acids; 2020 Apr; 52(4):511-521. PubMed ID: 32206932
[TBL] [Abstract][Full Text] [Related]
4. Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
Song X; Liu X; Ding X
J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27891677
[TBL] [Abstract][Full Text] [Related]
5. Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.
Meng S; Wu H; Wang J; Qiu Q
Mol Inform; 2016 Oct; 35(10):495-505. PubMed ID: 27712045
[TBL] [Abstract][Full Text] [Related]
6. Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
Lu J; Zhou K; Yin X; Xu H; Ma B
Comput Biol Chem; 2019 Feb; 78():290-296. PubMed ID: 30605854
[TBL] [Abstract][Full Text] [Related]
7. Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.
Wang YW; Zhang HY; Li JS; Wang XW
Chem Biodivers; 2017 Mar; 14(3):. PubMed ID: 27696725
[TBL] [Abstract][Full Text] [Related]
8. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.
Sohl CD; Ryan MR; Luo B; Frey KM; Anderson KS
ACS Chem Biol; 2015 May; 10(5):1319-29. PubMed ID: 25686244
[TBL] [Abstract][Full Text] [Related]
9. Hydrophobic Core Variations Provide a Structural Framework for Tyrosine Kinase Evolution and Functional Specialization.
Mohanty S; Oruganty K; Kwon A; Byrne DP; Ferries S; Ruan Z; Hanold LE; Katiyar S; Kennedy EJ; Eyers PA; Kannan N
PLoS Genet; 2016 Feb; 12(2):e1005885. PubMed ID: 26925779
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the inhibitor recognition of human Lyn kinase domain.
Miyano N; Kinoshita T; Nakai R; Kirii Y; Yokota K; Tada T
Bioorg Med Chem Lett; 2009 Dec; 19(23):6557-60. PubMed ID: 19857964
[TBL] [Abstract][Full Text] [Related]
11. On the origins of enzyme inhibitor selectivity and promiscuity: a case study of protein kinase binding to staurosporine.
Tanramluk D; Schreyer A; Pitt WR; Blundell TL
Chem Biol Drug Des; 2009 Jul; 74(1):16-24. PubMed ID: 19519740
[TBL] [Abstract][Full Text] [Related]
12. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
[TBL] [Abstract][Full Text] [Related]
13. Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state.
Besch A; Marsiglia WM; Mohammadi M; Zhang Y; Traaseth NJ
Proc Natl Acad Sci U S A; 2023 Feb; 120(8):e2213090120. PubMed ID: 36791110
[TBL] [Abstract][Full Text] [Related]
14. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
Mohi MG; Boulton C; Gu TL; Sternberg DW; Neuberg D; Griffin JD; Gilliland DG; Neel BG
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3130-5. PubMed ID: 14976243
[TBL] [Abstract][Full Text] [Related]
15. An interaction map of small-molecule kinase inhibitors with anaplastic lymphoma kinase (ALK) mutants in ALK-positive non-small cell lung cancer.
Ai X; Shen S; Shen L; Lu S
Biochimie; 2015 May; 112():111-20. PubMed ID: 25769414
[TBL] [Abstract][Full Text] [Related]
16. A general framework for inhibitor resistance in protein kinases.
Balzano D; Santaguida S; Musacchio A; Villa F
Chem Biol; 2011 Aug; 18(8):966-75. PubMed ID: 21867912
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
Rudrabhatla P; Rajasekharan R
Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase inhibition of clinically important staurosporine analogues.
Gani OA; Engh RA
Nat Prod Rep; 2010 Apr; 27(4):489-98. PubMed ID: 20336234
[TBL] [Abstract][Full Text] [Related]
19. Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology.
Wang Z; Jiang M; Feng N; Li C
Biochimie; 2018 Sep; 152():188-197. PubMed ID: 30017898
[TBL] [Abstract][Full Text] [Related]
20. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
Apsel Winger B; Cortopassi WA; Garrido Ruiz D; Ding L; Jang K; Leyte-Vidal A; Zhang N; Esteve-Puig R; Jacobson MP; Shah NP
Cancer Res; 2019 Aug; 79(16):4283-4292. PubMed ID: 31270078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
